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ABSTRACT
INTRODUCTION: The purpose of this study was to explore if 
there was a correlation between joint level and degree of 
contracture on the one hand and the risk of skin tear in Du­
puytren’s disease (DD) on the other, when treated with col­
lagenase from Clostridium histolyticum. No trial or study has 
explored the risk of skin tear as primary outcome in a popu­
lation that has not been treated for DD before.
METHODS: A retrospective study of prospectively collected 
data was performed on patients with DD treated with colla­
genase from 1 August 2012 to 1 April 2014. Skin tear was 
classified as “Yes” or “No” and not quantified by tear size 
for further analysis.
RESULTS: A total of 105 contractures in 90 patients with DD 
were included. In all, 77 contractures at the metacarpo­
phalangeal (MP) joint and 28 at the proximal interphalan­
geal joint (PIP) joint. A total of 59 contractures experienced 
skin tear. The relative risk (RR) of skin tear was 1.5 for an 
MP joint of ≥ 60° contracture compared with an MP joint at 
20­59° (p = 0.17). The RR of skin tear was 2.2 for a PIP joint 
of ≥ 60° contracture compared to a PIP joint of 20­59° (p = 
0.04). The RR for skin tear was 1.1 for an MP joint compared 
with the PIP joint (p = 0.74).  
The RR for skin tear was 1.7 for contractures of ≥ 60° com­
pared to 20­59° regardless of level (p = 0.01). 
CONCLUSIONS: There is a significantly higher relative risk of 
skin tear when the contracture is ≥ 60° and when the con­
tracture is ≥ 60° and located at the PIP joint. The most im­
portant factor regarding the risk of skin tear is the degree of 
the contracture. 
FUNDING: none.
TRIAL REGISTRATION: approved by the Danish Data Protec­
tion Agency. 
Dupuytren’s disease (DD) is a common illness affecting 
the palmar fascia of the hand causing potentially debili­
tating contractures of the hand. Several different treat­
ments are available; among these is injection of colla­
genase from Clostridium histolyticum. The physician 
injects collagenase into the affected Dupuytren’s cord. 
The following day, the contracture is manipulated to 
achieve rupture of the cord; thereby correcting the con­
tracture [1]. Some trials have explored the treatment of 
DD with collagenase injection followed by manual ma­
nipulation and reported an improved outcome [2­6]. The 
adverse event (AE) of skin tear is well known and men­
tioned in most studies [7­9]. To date, however, no study 
has investigated the risk of skin tear as a primary out­
come when treating DD with collagenase and manual 
manipulation. One study has described the AE of skin 
tear in 11% of all treated contractures, and another re­
ported 18% skin tear [10, 11]. We wanted to investigate 
if there was a higher risk of skin tear when the initial 
contracture was severe.
The aim of this study was to explore the connection 
between an affected joint and its degree of contracture 
relative to the likelihood of skin tear when manually  
manipulated the day after collagenase injection. The ob­
jectives were to determine the following: i) does severe 
contractures carry a higher risk of skin tear than less se­
vere contractures, and ii) are there differences between 
the risk of skin tear according to level, i.e. metacarpo­
phalangeal joint (MP), proximal interphalangeal joint 
(PIP) and distal interphalangeal joint (DIP)?
METHODS
Design
This was a retrospective study based on prospectively 
collected data. All patients with DD who were treated 
with collagenase from 1 August 2012 to 1 April 2014 in 
our clinic met the inclusion criteria and were enrolled in 
the study.
Contractures were measured before and after 
treatment, and any skin tear was noted in the patient’s 
files. Patients with skin tear were followed until total 
wound healing.
All patients were examined, treated and followed 
by a single physician. Relevant data were entered into a 
database (Excel) and extracted from the database for 
further analysis to meet the aims and purpose of the 
study. 
Patients
Patients referred by their physician to the orthopaedic 
department from 1 August 2012 to 1 April 2014 were 
enrolled in the study if they met the inclusion criteria.  
Eligible patients were ≥ 18 years old, had not previously 
been treated for DD on the specific finger, had a palp­
able cord on clinical exam, had a joint contracture ≥ 20° 
for either the MP joint or the PIP joint and had given 
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their written consent. The exclusion criteria were aller­
gies to collagenase or other contents in the product 
used, coagulation disease, ongoing treatment with tetra­
cyclines, fluoroquinolone or anticoagulant medicine that 
could not be paused for five days, wounds on the spe­
cific finger, receiving other clinical trial medicine or for­
mer nerve or skin lesions on the specific finger. No pa­
tients were excluded. We chose to divide the degree of 
contracture into two groups when comparing the risk of 
skin tear. One group included contractures of 20­59°, 
and the other included contractures of ≥ 60°.
Technique
The treatment was performed in the course of two days. 
On day one, the passive degree of contracture was 
measured, and the physician’s case report form was ini­
tiated. The measurement was done using a goniometer, 
and 0.58 mg collagenase was injected 0.5 cm proximally 
to the distal palmar crease if the contracture was at the 
MP joint and 0.58 mg was injected 0.5 cm distally to the 
palmar digital crease if the contracture was at the PIP 
joint. 0.58 mg collagenase was injected into the cord on 
both joint levels, as this is the recommended dose when 
treating Dupuytren’s contractures with collagenase [1]. 
Patients were instructed to keep the treated hand ele­
vated and at rest until the next day, and they were 
asked not to manipulate the finger themselves. They 
were told to take painkillers in case of pain.
On day two, the specific finger was injected with 4­5 
ml lidocain 2% in the area of the first injection. After 20 
minutes, the physician manipulated the finger to attempt 
rupture of the cord. After manipulation, the remaining 
passive degree of contracture was recorded in the case 
report form, as was the event of skin tear, if present. One 
consultant orthopaedic surgeon did the injection, mani­
pulation and measurement in accordance with the guide­
lines. If the patient experienced skin tear, the tear was 
treated in accordance with the guidelines for wound 
treatment and the patient was seen at extra follow­ups by 
a designated specially trained nurse, accompanied by the 
consultant surgeon, until the wound had totally healed. 
All patients were seen at a three­month follow­up.
Assessment
The consultant orthopaedic surgeon used a goniometer 
to measure the degree of contracture before and after 
the manual manipulation. The degree of contracture and 
the joint level of contracture were recorded in the phys­
ician’s case report form. Skin tear was recorded as pre­
sent or not and not, quantified by tear size. A goniom­
eter was also used at the three­month follow­up and 
data were entered in the case report form. The same 
consultant orthopaedic surgeon did all the measure­
ments. Data were transferred to a database in Excel for 
analysis.
Statistics
Fisher’s exact test and the chi­squared test were used 
when calculating the RR and p­values. An independent 
statistician from The University of Copenhagen, Den­
mark, calculated the statistics.
 
FIGURE 2
Distribution of cases in groups of contracture.
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FIGURE 1
An adverse event in the form of skin tear after manipulation on day two.
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Trial registration: The study was approved by The Danish 
Data Protection Agency. 
RESULTS
Overall
A total of 90 patients were enrolled. Seven patients 
were represented twice, and four patients were repre­
sented three times; thus, a total of 105 contractures in 
90 patients were included in the study. No patient re­
ceived the treatment twice in the same finger.
There were 88 (84%) contractures in males (the  
median age was 67 years) and 17 (16%) contractures in 
females (the median age was 68 years). Of the entire 
group, 59 (56%) contractures experienced skin tear 
when manipulated on day two. Figure 1 shows an ex­
ample of skin tear.
We found 77 (73%) contractures with the con­
tracted cord at the MP joint and 28 (27%) contractures 
at the PIP joint. No patient had the contracted cord at 
the level of the DIP joint. 
The distribution of contractures in different groups 
of degree is shown in Figure 2.
Distribution
A total of 67 contractures were found at the MP joint 
with a degree of contracture between 20° and 59°,  
and 36 (54%) of those experienced skin tear. Ten con­
tractures were found at the MP joint with a contracture 
≥ 60° and eight (80%) of those experienced skin tear. 
The distribution is shown in Table 1.
We found 20 contractures at the PIP joint with a 
contracture between 20° and 59° and eight (40%) of 
those experienced skin tear. Eight contractures were 
found at the PIP joint with a contracture ≥ 60° and seven 
(88%) of those experienced skin tear. The distribution is 
shown in Table 1.
Statistics
For our first objective, the RR for skin tear was 1.7 (p = 
0.01) for contractures ≥ 60° compared with 20­59° re­
gardless of joint level. For our secondary objective, the 
RR of skin tear was 1.5 for the MP joint of ≥ 60° contrac­
ture compared with the MP joint at 20­59° (p = 0.17). 
The RR of skin tear was 2.2 for the PIP joint of ≥ 60° con­
tracture compared with the PIP joint at 20­59° (p = 
0.04). The RR for skin tear was 1.1 (p = 0.74) for the MP 
joint compared with the PIP joint. The statistics are 
shown in Table 1.
DISCUSSION
In this study, we found an association between the joint 
level and the degree of contracture and the risk of skin 
tear. 
This finding can be used to inform patients con­
sidering collagenase treatment. Patients with severe 
contractures could consider other treatment modalities. 
We found no post procedure infections among patients 
with skin tears. Although a skin tear could be perceived 
as a coarse AE to the patient, it is our opinion that it is 
but a minor AE with minor long­term risks. Our results 
showed a higher number of skin tears compared with 
previous studies [11]. An explanation could be that our 
manual manipulation technique is less considerate than 
that of other physicians. However, none of the previous 
studies at hand were comparable as they describe DD in 
the thumb or treatment of more than one cord [7]. 
We are confident that our results are representa­
tive as we have tried to minimise the influence of ex­
ternal bias by excluding tissue softeners of any kind used 
to reduce the risk of skin tear before manipulation. 
Limitations of the study include that we subdivided the 
degrees of contracture into the two groups prior to the 
demographic findings. This subdivision turned out to be 
rather arbitrary and could have comprised another 
group including for example 35­50° of contracture. This 
group of patients has functional difficulties and is there­
fore more likely to seek treatment for DD than patients 
with a minor contracture. A subdivision into three 
groups might have shown an even higher risk of skin 
tear in patients with a severe contracture compared 
with patients with a minor contracture. Another limita­
tion is that we did not stratify for co­morbidities, alcohol 
consumption or smoking habits. We did not record the 
size of skin tear or actual duration of wound healing in 
patients with skin tear. No records were kept to estab­
lish if or for how long the skin tears kept patients from 
TABLE 1
Distribution of level of contracture, degree and relative risk from compared groups.
No skin  
tear, n
Skin tear,  
n (%)
Total,  
n (%)
RR of  
skin lesion p-value
Level
MP:
20°­59° 31 36 (54)   67 (64) ­ ­
≥ 60°   2   8 (80)   10 (10) ­ ­
Subtotal 33 44 (57)   77 (73) ­ ­
PIP:
20°­59° 12   8 (40)   20 (19) ­ ­
≥ 60°   1   7 (88)     8 (8) ­ ­
Subtotal 13 15 (54)   28 (27) ­ ­
All 46 59 (56) 105 (100) ­ ­
Characteristic
MP, ≥ 60° vs 20°-59° ­ ­ ­ 1.5 0.17
PIP, ≥ 60° vs 20°-59° ­ ­ ­ 2.2 0.04
MP vs PIP, all degrees ­ ­ ­ 1.1 0.74
≥ 60° vs 20°-59°, all levels ­ ­ ­ 1.7 0.01
MP = metacarpophalangeal joint; PIP = proximal interphalangeal joint; RR = relative risk.
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returning to their normal occupation. The patients with 
skin tear were seen the day after treatment by a desig­
nated nurse in the outpatient clinic and again 2­3 times 
more until healing. The mean time that patients with 
skin tear were unable to attend their job was assumed 
to be about two weeks, but we have no record of the ac­
tual time span. This is an important point if one wishes 
to analyse the cost­benefit of the treatment in future 
studies. 
The strength of the study was that a single consult­
ant orthopaedic surgeon carried out the measurement 
and treatment of the contractures making the treatment 
and measurements consistent. However, we do not 
know if the treatment is representative of the standard 
treatment done by other orthopaedic surgeons with re­
spect to the actual injection point of collagenase and the 
manual technique used to attempt rupture on day two. 
It is our belief that even though skin tear occurs, 
treatment with collagenase in Dupuytren’s contracture 
is more considerate, less invasive and overall less costly 
than open surgery. 
CONCLUSIONS
In collagenase treatment of Dupuytren’s contracture, we 
found a significantly higher relative risk of skin tear in 
joint contracture exceeding 60°, and the highest risk in 
contractures exceeding 60° and located at the PIP joint.
We found the risk of skin tear to be independent of 
joint level.
Therefore, focus is needed on patients with a con­
tracture exceeding 60°. Further investigation is warrant­
ed to determine if a kind of tissue softener, different 
manual manipulation technics or e.g. a time span of two 
days before manipulation may decrease the risk of skin 
tear when treating Dupuytren’s contracture with colla­
genase. Also, a cost­benefit comparison of collagenase 
treatment versus open surgery is relevant.
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